7 deficiency for one gene, but a minority of participants were knockouts for more than one 131 gene and one participant had six genes completely inactivated. The F inbreeding 132 coefficient was correlated with the number of homozygous null genes present in each 133 individual. (Spearman r = 0.29; P = 3 x 10 -133 ) (Fig. 3B) . 134 We tested the hypothesis that genes observed in the homozygous null state in 135 PROMIS participants are under less evolutionary constraint. We calculated the 136 probability of being loss-of-function intolerant (at >90% threshold) for each gene (see 137
Methods)
9,10 and. compared this to 961 randomly selected genes. The observed 961 138 homozygous null genes were less likely to be classified as highly constrained (odds ratio 139 0.10; 95% CI 0.095, 0.11; P < 1 x 10 -10 ). 140
We next sought to understand the phenotypic consequences of complete 141 disruption of any of these 961 genes. We applied two approaches. First, for 264 genes 142 where two or more participants were homozygous null, we conducted an association 143 screen against a panel of 201 phenotypic traits (Supplementary Table 2) . Second, at a 144 single gene, we recalled participants based on genotype across three classes ('wild-type', 145 heterozygous null, and homozygous null) and performed provocative physiologic testing. 146
At 264 genes where two or more participants were homozygous null, we 147 performed association analyses to determine whether homozygous null mutation status 148 Table 3 ). Below, we highlight four associations 159 demonstrating examples of 1) confirmed biochemical deficiency with two independent 160 assays (PLA2G7), 2) gene-biomarker association (CYP2F1), 3) pure recessive model of 161 association (A3GALT2), and 4) confirmed biochemical deficiency with gene-biomarker 162
association (APOC3). 163
Lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by PLA2G7) 164 hydrolyzes oxidatively-modified polyunsaturated fatty acids producing 165 lysophosphatidylcholine and oxidized nonesterified fatty acids. Higher soluble Lp-PLA2 166 activity has been correlated with higher risk for cardiovascular disease.
11 At PLA2G7, we 167 identified two participants homozygous for PLA2G7 c.663+1G>A. When compared with 168 non-carriers, c.663+1G>A homozygotes have markedly lower Lp-PLA2 enzyme as well 169 as activity (-266 ng/ml, P = 7 x 10 -5 for mass; -245 nmol/ml/min, P = 2 x 10 -7 for 170 activity) whereas the 102 heterozygotes had an intermediate effect (-107 ng/ml, P = 4 x 171
10
-26 for mass; -115 nmol/ml/min, P = 3 x 10 -58 for activity) (Supplementary Figure 3a-172 
b). 173
Cytochrome P450 2F1 (encoded by CYP2F1) is primarily expressed in the lung 174 and metabolizes pulmonary-selective toxins, such as cigarette smoke, and thus, 175 modulates the expression of environmentally-associated pulmonary diseases. 12 At 176 9 CYP2F1, we identified two participants homozygous for a splice-site mutation, c.1295-177 2A>G. When compared with non-carriers, c.1295-2A>G homozygotes displayed higher 178 soluble interleukin 8 concentrations (+40.3 %; P = 3 x 10 -6 ) (Supplementary Figure 4) . 179 CYP2F1 c.1295-2A>G heterozygotes (n = 3 assayed for interleukin 8) had a more modest 180 effect (+10.7 %; P = 2 x 10 -4 ). Interleukin 8 is a mediator of acute pulmonary 181 inflammation.
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182
Alpha-1,3-galactosyltransferase 2 (encoded by A3GALT2) catalyzes the formation 183 of the Gal-α1-3Galβ1-4GlcNAc-R (α-gal) epitope; the biological role of this enzyme in 184 humans is uncertain.
14 At A3GALT2, we identified two participants homozygous for a 185 frameshift mutation, p.Thr106SerfsTer4. Compared with non-carriers, p.Thr106SerfsTer4 186 homozygotes had both reduced fasting insulin C-peptide (-97.4%; P = 6 x 10 -12 ) as well 187 as total fasting insulin concentrations (-91.9%; P = 1 x 10 -4 ). Such an association was 188 only observed in the homozygous state (Supplementary Figure 5) . A3galt2 -/-mice and 189 pigs have recently been shown to have glucose intolerance.
15,16
190
To understand if the identification of only a single homozygote in PROMIS may 191 still be informative, we performed a complementary analysis, focusing on those with the 192 most extreme standard Z scores (|Z score| > 5) and requiring that there be evidence for 193 association in heterozygotes as well (see Methods). This procedure highlighted neureglin 194 4 (NRG4), a member of the epidermal growth factor family extracellular ligands which is 195 highly expressed in brown fat, particularly during adipocyte differentiation. 17, 18 At NRG4, 196
we identified a single participant homozygous for a frameshift mutation, 197 p.Ile75AsnfsTer23, who had nearly absent fasting insulin C-peptide concentrations (-99.3 198 %; P = 7 x 10 -11 ). When compared with non-carriers, heterozygotes for NRG4 199 p.Ile75AsnfsTer23 (n = 7) displayed 54.5 % reduction in insulin C-peptide (P = 6 x 10 -3 ). near-absent plasma apoC-III protein (-89.4 %, P = 5 x 10 -24 ), lower plasma triglyceride 211 concentrations (-61.7 %, P = 4 x 10 -4 ), higher high-density lipoprotein (HDL) cholesterol 212 (+28.1 mg/dL, P = 6 x 10 -9 ); and similar levels of low-density lipoprotein (LDL) 213 cholesterol (P = 0.11) (Fig. 4a-d) . 214
ApoC-III functions as a brake on the metabolism of dietary fat and thus, the 215 complete lack of this protein should promote handling of ingested fat. The availability of 216 humans completely deficient in APOC3 allowed us to test this hypothesis directly. We re-217 contacted one homozygous null proband, his wife, and 27 of his first-degree relatives for 218 genotyping and physiologic investigation. Surprisingly, we found that the proband's wife 219 was also a null homozygote, leading to all nine children being obligate homozygotes 220 (Fig. 4e) . In this family, we challenged homozygotes (n = 6) and non-carriers (n = 7) with 221 a 50 g/m 2 oral fat load followed by serial blood testing for six hours. APOC3 p.Arg19Ter 222 carriers had significantly lower post-prandial triglyceride excursions (triglycerides area 223 under the curve 468.3 mg/dL*6 hours vs 1267.7 mg/dL*6 hours; P = 1 x 10 -4 ) (Fig. 4f) . 224
These data show that complete lack of APOC3 markedly improves clearance of plasma 225 triglycerides after a fatty meal. 226 Gene disruption in model organisms followed by phenotypic analysis has been a 227 fruitful approach to understand gene function; here, we extend this concept to the human 228 organism, leveraging naturally-occurring null mutations, consanguinity, and extensive 229 biochemical phenotyping. These results permit several conclusions. among >100,000 participants in Iceland, 1107 homozygous null genes were identified 243 whereas we observe nearly the same number of null genes after analysis of about 7,000 244
Pakistanis. Third, recall of complete human knockouts followed by provocative testing may provide 248 physiologic insights. We used this approach to demonstrate that complete lack of 249 apolipoprotein C-III is tolerated and results in both lowered fasting triglyceride 250 concentrations as well as blunted post-prandial lipemia. Finally, to date, most human 251 genetic studies have pursued a phenotype-first ("forward" genetics) approach, beginning 252 with traits of interest followed by genetic mapping. Here, we show that it is now possible 253 to pursue a systematic genotype-first ("reverse" genetics) approach, starting with 254 homozygous null humans followed by methodical examination of a diverse set of traits. 255
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Methods 257
General overview of the Pakistan Risk for Myocardial Infarction Study (PROMIS). 258
The PROMIS study is designed to investigate determinants of cardiometabolic diseases 259 in Pakistan. Since 2005, the study has enrolled close to 38,000 participants; the present 260 investigation included 7,078 participants. Participants aged 30-80 years were enrolled 261 from nine recruitment centers based in five major urban cities in Pakistan. Type 2 262 diabetes in the study was defined based on self-report or fasting glucose levels >125 263 mg/dL or HbA1c > 6.5 % or use of glucose lowering medications. The study was 264 Pakistan, where serum and plasma samples were aliquoted across 10 different storage 274 vials. Samples were stored at -70°C for any subsequent laboratory analyses. All 275 biochemical assays were conducted in automated auto-analyzers. At CNCD Pakistan, 276 measurements for total-cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and 277 creatinine were made in serum samples using enzymatic assays; whereas levels of HbA1c 278
were measured using a turbidemetric assay in whole-blood samples (Roche Diagnostics, 279 on dry ice to the Smilow Research Center, University of Pennsylvania, USA, where 281 following biochemical assays were conducted: apolipoproteins (apoA-I, apoA-II, apoB, 282 apoC-III, apoE) and non-esterified fatty acids were measured through 283 immunoturbidometric assays using kits by Roche Diagnostics or Kamiya; lipoprotein (a) 284 levels were determined through a turbidimetric assay using reagents and calibrators from 285
Denka Seiken (Niigata, Japan); LpPLA2 mass and activity levels were determined using 286 immunoassays manufactured by diaDexus (San Francisco, CA, USA); measurements for 287 insulin, leptin and adiponectin were made using radio-immunoassays by LINCO (MO, 288 USA); levels of adhesion molecules (ICAM-1, VCAM-1, P-and E-Selectin) were 289 determined through enzymatic assays by R&D (Minneapolis, MN, USA); and 290 measurements for C-reactive protein, alanine transaminase, aspartate transaminase, 291 cystatin-C, ferritin, ceruloplasmin, thyroid stimulating hormone, alkaline phosphatase, 292 sodium, potassium, choloride, phosphate, sex-harmone binding globulin were made using 293 enzymatic assays manufactured by Abbott Diagnostics (NJ, USA). Glomerular filtration 294 rate (eGFR) was estimated from serum creatinine levels using the MDRD equation. 295
ApoC-III levels were determined in an autoanalyzer using a commercially available 296 ELISA by Sekisui Diagnostics (Lexington, USA). We also measured the following 52 297 protein biomarkers by multiplex immunoassay using a customised panel on the Luminex 298 100/200 instrument by RBM (Myriad Rules Based Medicine, Austin, TX, USA): fatty 299 acid binding protein, granuloctye monocyte colony stimulating factor, granulocyte colony 300 stimulating factor, interferon gamma, interleukin-1 beta, interleukin 1 receptor, 301 interleukin 2, interleukin 3, interleukin 4, interleukin 5, interleukin 6, interleukin 7, 302 interleukin 8, interleukin 10, interleukin 18, interleukin p40, interleukin p70, interleukin 303 15, interleukin 17, interleukin 23, macrophage inflammatory protein 1 alpha, macrophage 304 inflammatory protein 1 beta, malondialdehyde-modified LDL, matrix metalloproteinase 305 2, matrix metalloproteinase 3, matrix metalloproteinase 9, nerve growth factor beta, 306 tumor necrosis factor alpha, tumor necrosis factor beta, brain-derived neurotrophic factor, 307 CD40, CD40 ligand, eotaxin, factor VII, insulin-like growth factor 1, lecithin-type 308 oxidized LDL receptor 1, monocyte chemoattractant protein 1, myeloperoxidase, N-309 terminal prohormone of brain natriuretic peptide, neuronal cell adhesion molecule, 310 pregnancy-associated plasma protein A, soluble receptor for advanced glycation end-311 products, sortilin, stem cell factor, stromal cell-derived factor 1, thrombomodulin, S100 312 calcium binding protein B, and vascular endothelial growth factor. 313
314
Laboratory methods for array-based genotyping. 315
As previously described, a genomewide association scan was performed using the 316 Illumina 660 Quad array at the Wellcome Trust Sanger Institute (Hinxton, UK) and using 317 the Illumina HumanOmniExpress at Cambridge Genome Services, UK. 22 Initial quality 318 control (QC) criteria included removal of participants or single nucleotide 319 polymorphisms (SNPs) that had a missing rate >5%. SNPs with a MAF <1% and a P-320 value of <10 -7 for the Hardy-Weinberg equilibrium test were also excluded from the 321 analyses. In PROMIS, further QC included removal of participants with discrepancy 322 between their reported sex and genetic sex determined from the X chromosome. To 323 identify sample duplications, unintentional use of related samples (cryptic relatedness) 324 and sample contamination (individuals who seem to be related to nearly everyone in the 325 sample), identity-by-descent (IBD) analyses were conducted in PLINK. with probes specific to the ends of the adapters. This assay was automated using 364 Agilent's Bravo liquid handling platform. Based on qPCR quantification, libraries were 365 normalized to 2nM and pooled by equal volume using the Hamilton Starlet. Pools were 366 then denatured using 0.1 N NaOH. Finally, denatured samples were diluted into strip 367 tubes using the Hamilton Starlet. human reference (hg19) using Burrows-Wheeler Aligner (BWA). 27 Aligned reads 378 duplicating the start position of another read were flagged as duplicates and not analysed. 379
Data was processed using the Genome Analysis ToolKit (GATK v3).
28-30 Reads were 380 locally realigned around indels and their base qualities were recalibrated. Variant calling 381 was performed on both exomes and flanking 50 base pairs of intronic sequence across all 382 samples using the HaplotypeCaller (HC) tool from the GATK to generate a gVCF. Joint 383 genotyping was subsequently performed and 'raw' variant data for each sample was 384 formatted (variant call format (VCF)). SNVs and indel sites were initially filtered after 385 variant calibration marked sites of low quality that were likely false positives. 386 Data analysis QC. Fingerprint concordance between sequence data and fingerprint 387 genotypes was evaluated. Variant calls were evaluated on both bulk and per-sample 388
properties: novel and known variant counts, transition-transversion (TS-TV) ratio, 389
heterozygous-homozygous non-reference ratio, and deletion/insertion ratio. 
annotated. 398
Sample level quality control. We performed quality control of samples using the 399 following steps. For quality control of samples, we used bi-allelic SNVs that passed the 400 GATK VQSR filter and were on genomic regions targeted by both ICE and Agilent 401 exome captures. We removed samples with discordance rate > 10% between genotypes 402 from exome sequencing with genotypes from array-based genotyping and samples with 403 sex mismatch between inbreeding coefficient on chromosome X and fingerprinting. We 404 tested for sample contamination using the verifyBamID software, which examines the 405 proportion of non-reference bases at reference sites, and excluded samples with high 406 estimated contamination (FREEMIX scores > 0.2).
32 After removing monozygotic twins 407 or duplicate samples using the KING software 33 , we removed outlier samples with too 408 many or too few SNVs (>17,500 total variants for Agilent-captured samples or >18,000 409 for ICE-captured samples; <12,000 total variants; >600 singletons; and >400 doubletons). 410
We removed those with extreme overall transition-to-transversion ratios (>4 or <3) and 411 heterozygosity (heterozygote-to-homozygote ratio >6 or <2). Finally, we removed 412 samples with high missingness (>0.05). were permitted within a segment) were defined to be in a homozygous state (or referred 427 as "runs of homozygosity" (ROH)), as described previously. 34 Homozygosity was 428 Genetics consortium. 25 We extracted approximately 5,000 high-quality polymorphic 440
SNVs in linkage equilibrium present on both target intervals that passed variant quality 441 control metrics based on HapMap 3 data. 35 Using PLINK, we estimated the coefficient of 442 inbreeding separately within each ethnicity group. 23 The coefficient of inbreeding was 443 estimated as the observed degree of homozygosity compared with the anticipated 444 homozygosity derived from an estimated common ancestor. 36 The Wilcoxon-Mann-445
Whitney test was used to test whether PROMIS participants had different median 446 coefficients of inbreeding compared to other similarly sequenced outbred individuals and 447 whether the median coefficient of inbreeding was different between PROMIS participants 448 who reported parental relatedness versus not. A two-sided P of 0.05 was the pre-specified 449 threshold for statistical significance. 450
451
Methods for sequencing projection analysis. 452
To compare the burden of unique completely inactivated genes in the PROMIS cohort 453 with outbred cohorts of diverse ethnicities, we extracted the minor allele frequencies 454 (maf) of "high confidence" loss-of-function mutations observed in PROMIS, and in 455 European, African, and East Asian ancestry participants from the Exome Aggregation 456 Consortium (ExAC r0.3; exac.broadinstitute.org). For each gene and for each ethnicity, 457 the combined minor allele frequency (cmaf) of rare (maf < 0.1%) "high confidence" loss-458 of-function mutations was calculated. We then simulated the number of unique 459 completely inactivated genes across a range of sample sizes per ethnicity and PROMIS. 460
The expected probability of observing complete inactivation (two null copies in an 461 individual) of a gene was calculated as (1 − ) * ! + * , which accounts 462 for allozygous and autozygous, respectively, mechanisms for complete genie knockout. 463 F, the inbreeding coefficient, is defined as = 1 − ( ℎ / 464 ℎ ). For PROMIS, the median F inbreeding coefficient 465 (0.016) was used for estimation. Down-sampling within the observed sample size for 466 both high-confidence null mutations and synonymous variants did not deviate 467 significantly from the expected trajectory. For a range of sample sizes (0-200,000), each 468 gene was randomly sampled under a binomial distribution ( ~ ( , )) and it was 469 determined if the gene was successfully sampled at least once. To refine the estimated 470 count of unique genes per sample size, each sampling was replicated ten times. 471
472
Methods for constraint score analysis. 473
We sought to determine whether the observed homozygous null genes were under less 474 evolutionary constraint by first obtaining constraint loss of function constraint scores 475 derived from the Exome Aggregation Consortium (Lek M et al, in preparation).
9,10
476
Briefly, we used the number of observed and expected rare (MAF < 0.1%) loss of 477 function variants per gene to determine to which of three classes it was likely to belong: 478 null (observed variation matches expectation), recessive (observed variation is ~50% 479 expectation), or haploinsufficient (observed variation is <10% of expectation). The 480 probability of being loss of function intolerant (pLI) of each transcript was defined as the 481 probability of that transcript falling into the haploinsufficient category. Transcripts with a 482 pLI ≥ 0.9 are considered very likely to be loss of function intolerant; those with pLI ≤ 0. For all analyses, we constructed generalized linear models to test whether complete loss 499 of function versus non-carriers was associated with trait variation. A logit link was used 500 for binomial outcomes. Right-skewed continuous traits were natural log transformed. 501
Age, sex, and myocardial infarction status were used as covariates in all analyses. We 502 extracted principal components of ancestry using EIGENSTRAT to control for 503 population stratification in all analyses.
37 For lipoprotein-related traits, the use of lipid-504 lowering therapy was used as a covariate. For glycemic biomarkers, only non-diabetics 505
were used in the analysis. The P threshold for statistical significance was 0.05 / 15,263 = 506 3 x 10 -6 . 507 24 Heterozygote association replication. We hypothesized that some of the associations 508 for homozygous nulls will display a more modest effect for heterozygous nulls. Thus, the 509 aforementioned analyses were performed comparing heterozygous nulls to non-carriers 510 for the fourteen homozygous null-trait associations that surpassed prespecified statistical 511 significance. A P of 0.05 / 13 = 0.004 was set for statistical significance for these 512 restricted analyses. 513
Association for single genic homozygotes. We performed an exploratory analysis of 514 gene-trait pairs where there was only one phenotyped homozygous null. We performed 515 the above association analyses for genes where there was only one homozygous null 516 phenotyped for a given trait and we focused on those with the most extreme standard Z 517 score statistics (|Z score| > 5) from the primary association analysis and required that 518 there to also be nominal evidence for association (P < 0.05) in heterozygotes as well to 519 maximize confidence in an observed single homozygous null-trait association. 520
521
Methods for recruitment and phenotyping of an APOC3 p.Arg19Ter proband and 522
relatives. 523
Methods for Sanger sequencing. We collected blood samples from a total of 28 524 subjects, including one of the four APOC3 p.Arg19Ter homozygous participants along 525 with 27 of his family and community members for DNA extraction and separated into 526 plasma for lipid and apolipoprotein measurements. All subjects were consented prior to 527 initiation of the studies (IRB: 00007048 at the Center for Non-Communicable Diseases, 528 Paksitan). DNA was isolated from whole blood using a reference phenol-chloroform 529 protocol. 38 Genotypes for the p. and non-carriers using a two independent sample Student's t test; P < 0.05 was 546 considered statistically significant. 547
548
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